Results 1 to 10 of about 16,526 (218)

Molecular characterization of Echinocandin resistance and the CHS3-mediated adaptive response in Candida glabrata bloodstream infections in Eastern China [PDF]

open access: yesBMC Microbiology
Background Candidemia caused by Candida glabrata is a serious fungal infection, and rising echinocandin resistance presents a significant clinical challenge.
Peishan Cong   +7 more
doaj   +2 more sources

Clinical Case Report on the Use of Rezafungin in Pneumocystis jirovecii Pneumonia in a Critically Ill Patient [PDF]

open access: yesMicroorganisms
Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection predominantly affecting immunocompromised patients. Trimethoprim–sulfamethoxazole (TMP–SMX) remains the standard therapy but is often limited by severe toxicity ...
Rosario Fernández-Fernández   +4 more
doaj   +2 more sources

Profound cell wall remodeling in Candida parapsilosis during systemic infection confers simultaneous tolerance to echinocandins and host immunity [PDF]

open access: yesMicrobiology Spectrum
Antifungal tolerance can promote the emergence of resistance yet often incurs fitness costs for fungal pathogens. How tolerant populations compensate for these deficits and how they may be therapeutically targeted remain poorly understood.
Farnaz Daneshnia   +28 more
doaj   +2 more sources

Multifactorial Role of Mitochondria in Echinocandin Tolerance Revealed by Transcriptome Analysis of Drug-Tolerant Cells

open access: yesmBio, 2021
Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy.
Rocio Garcia-Rubio   +5 more
doaj   +1 more source

Curcumin Epigenetically Represses Histone Acetylation of Echinocandin B Producing Emericella rugulosa

open access: yesPhysiologia, 2023
Echinocandin B is a natural product that possesses potent antifungal property against a wide array of fungi. This antifungal agent is produced by Emericella rugulosa. The biosynthetic genes of echinocandin B are physically organized in two gene clusters (
Vandana Kumari   +3 more
doaj   +1 more source

Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. [PDF]

open access: yes, 2016
Aspergillus spp. are a group of filamentous molds that were first described due to a perceived similarity to an aspergillum, or liturgical device used to sprinkle holy water, when viewed under a microscope.
Stewart, Ethan R, Thompson, George R
core   +11 more sources

Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China

open access: yesBMC Microbiology, 2023
Background Candida glabrata is an important cause of invasive candidiasis. Echinocandins are the first-line treatment of invasive candidiasis caused by C. glabrata.
Yi Li   +15 more
doaj   +1 more source

Loss of Septation Initiation Network (SIN) kinases blocks tissue invasion and unlocks echinocandin cidal activity against Aspergillus fumigatus.

open access: yesPLoS Pathogens, 2021
Although considered effective treatment for many yeast fungi, the therapeutic efficacy of the echinocandin class of antifungals for invasive aspergillosis (IA) is limited.
Ana Camila Oliveira Souza   +6 more
doaj   +1 more source

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. [PDF]

open access: yesPLoS Pathogens, 2012
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for ...
Sheena D Singh-Babak   +9 more
doaj   +1 more source

Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center

open access: yesAntibiotics, 2023
Delays in the treatment of proven invasive fungal disease have been shown to be harmful. However, empiric treatment for all patients at risk of infection has not demonstrated benefit.
J. Myles Keck   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy